abstract |
ENZYME INHIBIT COMPOUNDS. One aspect of the invention relates to inhibitors which preferentially inhibit immunoproteasoma activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immunorelated diseases comprising administering a compound of the invention. In some embodiments, the invention relates to cancer treatment, which comprises administering a compound of the invention. |